Executives On The Move: Five CEOs And Four New CFOs Among This Week’s Changes
Recent moves in the industry include C-suite changes at Coya Therapeutics, Kancera and Verrica Pharmaceuticals, which acquires chief financial officer from Aceragen.
More from Executives On The Move
Recent moves in the industry include changes at the top at Mitsubishi Tanabe Pharma and MC2 Therapeutics, plus MindMed acquires chief financial officer from Longboard Pharma.
Pascal Soriot, CEO of AstraZeneca, joins Agilent Technologies' board, plus Zealand Pharma acquires chief development officer from UCB Biopharma.
Recent moves in the industry include new C-suite hires at Janux Therapeutics, BlueSphere Bio and Hansa Biopharma, plus Syndax Pharmaceuticals gets new chief medical officer from Bristol Myers Squibb.
Recent moves in the industry include changes at the top at Akamis Bio, Innospera Pharma & Ispen, plus Astellas Korea appoints an ex-Novartis Korea executive.
More from Scrip
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
In this week's episode: Sanofi’s Blueprint buy; AstraZeneca’s breast cancer resistance results at ASCO; BMS and BioNTech’s big bispecific deal; Kymera’s Dupixent in a pill; and Degron’s CEO on pipeline and strategy.
LTZ Therapeutics and Beijing Sungen Biomedical are among the Chinese biotechs raising new funding, of around $40m each, based on their clinical assets with novel mechanisms of action. While fundings have risen, they remain moderate however.